Pharmacology of G Protein Coupled Receptors: Volume 62

Pharmacology of G Protein Coupled Receptors: Volume 62

Volume editor 

Free delivery worldwide

Available. Dispatched from the UK in 1 business day
When will my order arrive?


G protein coupled receptors remain the most important class of therapeutic targets in medicine. In the last 5 years, tremendous advances have been made in our understanding of the structure and mechanism of this critical family of drug targets. The present volume explores the modern experimental and conceptual framework for drug discovery for G protein coupled receptors. It explores advances in structure determination and structure-based drug design as well as new concepts of allosteric modulation, functional selectivity/biased agonism, and pharmacological chaperones. In addition, emerging drug targets such as receptor families for fatty acids, carboxylic acids, lipid mediators, etc. are included. Final chapters cover novel mechanisms of signal regulation through PDZ domains and RGS proteins. This volume will bring an up-to-date perspective on the G protein coupled receptor field to both academic and industry scientists.
show more

Product details

  • Hardback | 408 pages
  • 152.4 x 228.6 x 22.86mm | 680.39g
  • Academic Press Inc
  • San Diego, United States
  • English
  • New
  • 0123859522
  • 9780123859525

Table of contents

The Use of GPCR Structures in Drug Design Miles Congreve, Christopher Langmead and Fiona Marshall
Allosteric Modulation of Metabotropic Glutamate Recetors Douglas J. Sheffler, Karen J. Gregory, Jerri M. Rook, and P. Jeffrey Conn
Refining Efficacy: Exploiting Functional Selectivity for Drug Discovery Diane Gesty-Palmer and Louis M. Luttrell
Pharmacoperones for Misfolded Gonadotropin - Releasing Hormone Receptors P. Michael Conn and Alfredo Ulloa-Aguirre
Regulation of Stability and Trafficking of Calcium Sensing Receptors by Pharmacologic Chaperones Ying Huang, Alice Cavanaugh, and Gerda E. Breitwieser
Experimental Challenges to Targeting Poorly Characterised GPCRs: Therapeutic Potential for Free Fatty Acid Receptor Brian D. Hudson, Nicola J. Smith and Graeme Milligan
Biological and Pharmacological Roles of HCA Receptors Clara Blad, Kashan Ahmed, Ad IJzerman, and Stefan Offermanns
Pharmacology, Signaling and Physiological Relevance of the G Protein-Coupled Receptor 55 (GPR55) Nariman Balenga, Julia Kargl and Maria Waldhoer
Role of PDZ Proteins in Regulating Signaling, Trafficking, and Function of GPCRs Paul Temkin, Mark von Zastrow, Peter A. Friedman, and Guillermo Romero
Regulator of G Protein Signaling Proteins as Drug Targets: Current State and Future Possibilities Benita Sjoegren
GPCR-Interacting Proteins, Major Players in GPCR Function Pascal Maurice, Maud Kamal, Avais Daulat, Jean-Luc Guillaume, and Ralf Jockers
show more

About S. J. Enna

Dr. S. J. Enna received his B.A. degree (1965, Biology) from Rockhurst University, Kansas City, Missouri and both his M.S. (1967, Pharmacology) and Ph.D. (1970, Pharmacology) degrees from the University of Missouri-Kansas City. Postdoctoral training in pharmacology was completed at the University of Texas Southwestern Medical School in Dallas, at F. Hoffmann La Roche in Basel, Switzerland, and the Department of Pharmacology and Experimental Therapeutics at Johns Hopkins University School of Medicine in Baltimore. Dr. Enna spent 10 years on the faculty at the University of Texas Medical School at Houston in the Departments of Pharmacology and Neurobiology. While at the University of Texas Dr. Enna was also a consultant for ICI USA, Inc., Merck, Sharp and Dohme Research Laboratories, Bristol Myers Corporation, and Panlabs, Inc. From 1986 1990, Dr. Enna was Senior Vice President and Scientific Director of Nova Pharmaceutical Corporation in Baltimore, and Executive Vice President from 1990 1992. He is currently Associate Dean for Research and Graduate Education as well as Professor of Physiology and of Pharmacology at the University of Kansas Medical School. Dr. Enna served as chair of the Department of Pharmacology, Toxicology and Therapeutics at the University of Kansas Medical School from 1992 to 2003. Other previous academic appointments include Lecturer in the Department of Neuroscience at The Johns Hopkins University School of Medicine in Baltimore and Adjunct Professor of Pharmacology at Tulane University School of Medicine in New Orleans. Dr. Enna served for six years as editor of The Journal of Pharmacology and Experimental Therapeutics, and is currently co-editor of Current Protocols in Pharmacology. He is also Editor-in-Chief of Biochemical Pharmacology, Executive Editor-in-Chief of Pharmacology and Therapeutics and Series Editor of Advances in Pharmacology. Besides his editorships, Dr. Enna serves on the editorial boards of Brain Research, Life Sciences and CNS Drug Reviews. He has been the recipient of Research Career Development Awards from the National Institute of Mental Health and the National Institute for Neurological, Communicative Disorders and Stoke. Other awards include the John Jacob Abel Award and the Torald Sollmann Award from the American Society for Pharmacology and Experimental Therapeutics, the Daniel H. Efron Award from the American College of Neuropsychopharmacology, and a PhARMA Foundation Excellence Award. In recent years he has been a member of the Scientific Advisory Council of Abbott Laboratories, has served on the Board of Directors of the Life Sciences Research Office, and on the Scientific Advisory Board of the National Alliance for Autism Research. He is currently a member of the Basic Pharmacology Advisory Committee of the PhARMA Foundation. Dr. Enna has held many elective offices in professional societies including the presidency of the American Society for Pharmacology and Experimental Therapeutics (ASPET). Since 2006 he has served as Secretary General of the International Union of Basic and Clinical Pharmacology (IUPHAR). Dr. Enna's research interests include neuropharmacology, neurochemistry and neuropsychiatric disorders. He has made significant contributions in defining the pharmacological and biochemical properties of neurotransmitter receptors, in particular those for GABA. He has also conducted research into the effects of hormones on neurotransmitter receptor function and receptor responses to psychotherapeutics, the development of receptor antagonists for NMDA, cholinergic muscarinic and bradykinin receptors, and the identification of the cellular components of coincident signaling in brain. Dr. Enna's research is described in over 200 published research reports, reviews, and book chapters. He has authored or edited over three dozen books on topics ranging from neuropharmacology in general, to neurotransmitter receptors and GABA.
show more